Drug intelligence / Profile preview

ampicillin + sulbactam + clindamycin

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Intravenous, Intramuscular, Oral
01

Overview

This is a combination of three antibiotics: ampicillin (a semisynthetic penicillin), sulbactam (a beta-lactamase inhibitor), and clindamycin (a lincosamide antibiotic). The combination is sometimes used in clinical practice for treating complex infections requiring broad-spectrum coverage. **Ampicillin + sulbactam** works by: - Ampicillin binds to penicillin-binding proteins (PBPs) to inhibit bacterial cell wall synthesis - Sulbactam inhibits beta-lactamase enzymes that would otherwise break down ampicillin, extending coverage against potentially resistant bacteria - Together they provide enhanced activity against many gram-positive and gram-negative bacteria **Clindamycin** works by: - Inhibiting bacterial protein synthesis by binding to 23S RNA of the 50S subunit of the bacterial ribosome - Providing excellent coverage against anaerobic bacteria This combination may be used for treating complex infections such as aspiration pneumonia, lung abscesses, and certain surgical site infections.

02

Targets

β-lactamasePBP1A (Penicillin-binding protein 1A)Bacterial 50S ribosomal subunitPBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on ampicillin + sulbactam + clindamycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ampicillin + sulbactam + clindamycin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call